NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals Inc (NASDAQ:XENE) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.16. The biopharmaceutical company earned $3.50 million during the quarter. View Xenon Pharmaceuticals' Earnings History.

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xenon Pharmaceuticals.

2 analysts have issued twelve-month target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $18.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 54.1% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.

Headlines about XENE stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Xenon Pharmaceuticals.

Xenon Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 527,900 shares, an increase of 8.0% from the October 31st total of 488,600 shares. Based on an average daily volume of 47,600 shares, the days-to-cover ratio is presently 11.1 days. Currently, 2.4% of the shares of the stock are short sold. View Xenon Pharmaceuticals' Current Options Chain.

Some companies that are related to Xenon Pharmaceuticals include Nabriva Therapeutics (NBRV), Athenex (ATNX), Esperion Therapeutics (ESPR), Innoviva (INVA), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Principia Biopharma (PRNB), ArQule (ARQL), NextCure (NXTC), Rocket Pharmaceuticals (RCKT) and Wave Life Sciences (WVE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sucampo Pharmaceuticals (SCMP), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Crispr Therapeutics (CRSP), Exelixis (EXEL), Fate Therapeutics (FATE) and Synergy Pharmaceuticals (SGYP).

Xenon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (2.34%), Granite Point Capital Management L.P. (1.15%), Granahan Investment Management Inc. MA (0.41%), Squarepoint Ops LLC (0.34%), California Public Employees Retirement System (0.24%) and Alps Advisors Inc. (0.20%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.

XENE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Granite Point Capital Management L.P., Squarepoint Ops LLC and Alps Advisors Inc.. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Insider Buying and Selling for Xenon Pharmaceuticals.

XENE stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Supplemental Annuity Collective Trust of NJ, Granahan Investment Management Inc. MA, California Public Employees Retirement System and Tower Research Capital LLC TRC . View Insider Buying and Selling for Xenon Pharmaceuticals.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XENE stock can currently be purchased for approximately $13.95.

Xenon Pharmaceuticals has a market capitalization of $360.87 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]